한글목차

이상지질혈증 치료제 동향과 전망

세계 이상지질혈증 치료제 시장은 2024년부터 2030년까지 9.4%의 연평균 복합 성장률(CAGR)로 2030년까지 약 440억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 당뇨병 및 이상지질혈증 환자 수 증가, 전 세계 노인 인구 증가, 콜레스테롤 수치 이상 및 지질 관련 질환의 빈도 증가 등입니다. 세계 이상지질혈증 치료제 시장의 미래는 병원 약국 및 소매 약국 시장에 기회가 있고 유망한 것으로 보입니다.

부문별 이상지질혈증 치료제

본 조사에서는 이상지질혈증 치료제 세계 시장을 약제 유형별, 용도별, 지역별로 예측했습니다.

이상지질혈증 치료제 시장 인사이트

Lucintel의 예측에 따르면, 스타틴 계열 약물은 예측 기간 동안 높은 성장을 보일 것으로 예상됩니다.

이 시장에서 병원 약국은 예측 기간 동안 계속해서 더 큰 부문을 차지할 것으로 보입니다.

북미는 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

자주 묻는 질문

Q1. 시장 규모 :

A1. 세계 이상지질혈증 치료제 시장은 2030년까지 약 440억 달러에 달할 것으로 예상됩니다.

Q2. 시장 성장 예측은 다음과 같습니다.

A2. 세계 이상지질혈증 치료제 시장은 2024년부터 2030년까지 연평균 9.4% 성장할 것으로 예상됩니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은 다음과 같습니다.

A3.이 시장의 주요 촉진요인은 당뇨병 및 이상지질혈증 환자 수 증가, 전 세계 노인 인구 수 증가, 콜레스테롤 수치 이상 및 지질 관련 질환의 빈도 증가입니다.

Q4. 시장의 주요 부문은 다음과 같습니다.

A4. 이상지질혈증 치료제 시장의 미래는 병원 약국 시장과 소매 약국 시장에서의 기회가 더 유망합니다.

Q5. 시장 주요 기업은 다음과 같습니다.

A5. 이상지질혈증 치료제 주요 기업은 다음과 같습니다.

• AstraZeneca
• Bayer
• Amgen
• Merck
• Shionogi
• Novartis
• Pfizer
• Bristol-Myers Squibb Company
• Mylan
• Abbott Laboratories

Q6. 향후 가장 큰 시장 부문은 다음과 같습니다.

A6. Lucintel은 예측 기간 동안 스타틴 계열의 약물이 높은 성장세를 보일 것으로 예상하고 있습니다.

Q7. 시장에서 향후 5년간 가장 큰 시장이 될 것으로 예상되는 지역은 어디입니까?

A7. 예측 기간 동안 북미가 가장 높은 성장을 보일 것으로 예상됩니다.

Q8. 보고서 사용자 정의가 가능합니까?

A8. 네. Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 이상지질혈증 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 이상지질혈증 치료제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 약제 유형별 이상지질혈증 치료제 세계 시장
  • 비스타틴계 약제
  • 스타틴계 약제
• 용도별 이상지질혈증 치료제 세계 시장
  • 병원 약국
  • 소매 약국
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 이상지질혈증 치료제 세계 시장
• 북미의 이상지질혈증 치료제 시장
• 유럽의 이상지질혈증 치료제 시장
• 아시아태평양의 이상지질혈증 치료제 시장
• 기타 지역의 이상지질혈증 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 이상지질혈증 치료제 시장 약제 유형별 성장 기회
  • 용도별 이상지질혈증 치료제 시장 성장 기회
  • 지역별 세계의 이상지질혈증 치료제 시장 성장 기회
• 세계 이상지질혈증 치료제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 이상지질혈증 치료제 시장 능력 확대
  • 세계 이상지질혈증 치료제 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증과 라이선싱

제7장 주요 기업 개요

• AstraZeneca
• Bayer
• Amgen
• Merck
• Shionogi
• Novartis
• Pfizer
• Bristol-Myers Squibb Company
• Mylan
• Abbott Laboratories

영문목차

Dyslipidaemia Drug Trends and Forecast

The future of the global dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030 with a CAGR of 9.4% from 2024 to 2030. The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Dyslipidaemia Drug by Segment

The study includes a forecast for the global dyslipidaemia drug by drug type, application, and region.

Dyslipidaemia Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Non-Statins Drugs
• Statins Drugs

Dyslipidaemia Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Dyslipidaemia Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Dyslipidaemia Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dyslipidaemia drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dyslipidaemia drug companies profiled in this report include-

• AstraZeneca
• Bayer
• Amgen
• Merck
• Shionogi
• Novartis
• Pfizer
• Bristol-Myers Squibb Company
• Mylan
• Abbott Laboratories

Dyslipidaemia Drug Market Insights

Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Within this market, hospital pharmacy will remain larger segment over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Dyslipidaemia Drug Market

Market Size Estimates: Dyslipidaemia drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dyslipidaemia drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Dyslipidaemia drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the dyslipidaemia drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dyslipidaemia drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the dyslipidaemia drug market size?

Answer: The global dyslipidaemia drug market is expected to reach an estimated $44.0 billion by 2030.

Q2. What is the growth forecast for dyslipidaemia drug market?

Answer: The global dyslipidaemia drug market is expected to grow with a CAGR of 9.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the dyslipidaemia drug market?

Answer: The major drivers for this market are rise in the number of diabetic and dyslipidemia patients, growing number of elderly people worldwide, and increasing frequency of abnormal cholesterol levels and lipid-associated disorders.

Q4. What are the major segments for dyslipidaemia drug market?

Answer: The future of the dyslipidaemia drug market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets.

Q5. Who are the key dyslipidaemia drug market companies?

Answer: Some of the key dyslipidaemia drug companies are as follows:

• AstraZeneca
• Bayer
• Amgen
• Merck
• Shionogi
• Novartis
• Pfizer
• Bristol-Myers Squibb Company
• Mylan
• Abbott Laboratories

Q6. Which dyslipidaemia drug market segment will be the largest in future?

Answer: Lucintel forecasts that statins drug is expected to witness higher growth over the forecast period.

Q7. In dyslipidaemia drug market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dyslipidaemia drug market by drug type (non-statins drugs and statins drugs), application (hospital pharmacy, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dyslipidaemia Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Dyslipidaemia Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Dyslipidaemia Drug Market by Drug Type
  • 3.3.1: Non-Statins Drugs
  • 3.3.2: Statins Drugs
• 3.4: Global Dyslipidaemia Drug Market by Application
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Dyslipidaemia Drug Market by Region
• 4.2: North American Dyslipidaemia Drug Market
  • 4.2.1: North American Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
  • 4.2.2: North American Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
• 4.3: European Dyslipidaemia Drug Market
  • 4.3.1: European Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
  • 4.3.2: European Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
• 4.4: APAC Dyslipidaemia Drug Market
  • 4.4.1: APAC Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
  • 4.4.2: APAC Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others
• 4.5: ROW Dyslipidaemia Drug Market
  • 4.5.1: ROW Dyslipidaemia Drug Market by Drug Type: Non-Statins Drugs and Statins Drugs
  • 4.5.2: ROW Dyslipidaemia Drug Market by Application: Hospital Pharmacy, Retail Pharmacy, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Dyslipidaemia Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Dyslipidaemia Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Dyslipidaemia Drug Market by Region
• 6.2: Emerging Trends in the Global Dyslipidaemia Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Dyslipidaemia Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dyslipidaemia Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: AstraZeneca
• 7.2: Bayer
• 7.3: Amgen
• 7.4: Merck
• 7.5: Shionogi
• 7.6: Novartis
• 7.7: Pfizer
• 7.8: Bristol-Myers Squibb Company
• 7.9: Mylan
• 7.10: Abbott Laboratories